跳至主要内容
临床试验/NCT03172897
NCT03172897暂停4 期

Low-dose Dexmedetomidine for Delirium Prevention in Mechanically Ventilated Patients in Intensive Care Unit: a Multicenter, Randomised, Double-blinded, Placebo-controlled Trial

Peking University First Hospital1 个研究点 分布在 1 个国家目标入组 260 人开始时间: 2017年8月20日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
暂停
入组人数
260
试验地点
1
主要终点
Incidence of delirium within the first 7 days after enrollment

研究概览

简要总结

For patients undergoing mechanical ventilation, light sedation is better than deep sedation for the outcomes, which is manifested as shortened length of ICU stay, shortened duration of mechanical ventilation, and decreased mortality. In a recent study of the investigators, low-dose dexmedetomidine without sedative effects (0.1 ug/kg/h) improved sleep quality and reduced the incidence of delirium in elderly patients admitted to the ICU after surgery. The investigators hypothesize that, for ICU patients with prolonged mechanical ventilation, low-dose dexmedetomidine infusion (0.1 ug/kg/h) may also be effective in decreasing delirium. The purpose of this study is to investigate whether low-dose dexmedetomidine infusion can reduce the incidence of delirium in ICU patients with prolonged duration of mechanical ventilation (>= 24 hours).

详细描述

Delirium is an acutely occurred and transient brain dysfunction characterized with cognitive dysfunction, lowered consciousness, disturbed attention, abnormal psychoactivity, and disordered sleep-wake rhythm. Delirium is frequent in mechanically ventilated patients in the intensive care unit (ICU), with reported incidences up to 70% or 87%. Possible reasons leading to delirium include the intervention-heavy environment of the ICU, mechanical ventilation and sleep disturbances. The occurrence of delirium is associated with worse outcomes including prolonged mechanical ventilation and ICU stay, increased complications, prolonged hospital stay, higher mortality, and elevated medical expenses. It is also associated with worse long-term outcomes including declined cognitive function, lowered life quality, and elevated long-term mortality.

Dexmedetomidine is a high selective alpha-2 adrenoceptor agonist with anxiolytic, sedative and analgesic effects. When used for sedation in mechanically ventilated patients (dose range 0.2-1.4 ug/kg/h), it reduces the consumption of other sedatives and analgesics, ameliorates the rhythm and structure of sleep, and decreases the occurrence of delirium. In recent studies of the investigators, low-dose dexmedetomidine infusion (0.1 ug/kg/h) ameliorated sleep quality; for elderly patients admitted to the ICU after surgery, prophylactic low-dose dexmedetomidine infusion reduced the incidence of delirium (for patients with mechanical ventilation: 28.8% with placebo vs. 11.5% with dexmedetomidine, P<0.0001; for patients without mechanical ventilation: 15.1% with placebo vs. 6.3% with dexmedetomidine, P=0.014).

For patients undergoing mechanical ventilation, light sedation is better than deep sedation for the outcomes, which is manifested as shortened length of ICU stay, shortened duration of mechanical ventilation, and decreased mortality. Some authors even reported that no sedation (analgesia only) provides better outcome than light sedation, because it further shortens the durations of mechanical ventilation and ICU stay. In the above studies of the investigators, the recruited patients were less severe because the Acute Physiology and Chronic Health Evaluation II (APACHE II) score was low (mean score from 10.2 to 10.6) and the duration of mechanical ventilation was short (median 6.9 hours in the control group). The investigators hypothesize that, for ICU patients with prolonged mechanical ventilation, low-dose dexmedetomidine infusion (0.1 ug/kg/h) may also be effective in improving sleep and decreasing delirium. The purpose of this study is to investigate whether low-dose dexmedetomidine infusion can reduce the incidence of delirium in ICU patients with prolonged duration of mechanical ventilation (>= 24 hours).

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • aged 18 years or older;
  • admitted to the ICU;
  • with expected duration of mechanical ventilation of more than 24 hours.

排除标准

  • refused to participate;
  • aged less than 18 years;
  • pregnant;
  • preoperative history of schizophrenia, epilepsy, Parkinsonism, or myasthenia gravis;
  • inability to communicate in the preoperative period (coma, profound dementia, or language barrier);
  • brain injury or neurosurgery;
  • known preoperative left ventricular ejection fraction less than 30%, sick sinus syndrome, severe sinus bradycardia (<50 beats per min [bpm]), or second degree or greater atrioventricular block without pacemaker;
  • severe hepatic dysfunction (Child-Pugh class C);
  • severe renal dysfunction (undergoing dialysis before surgery);
  • less likely to survive for more than 24 hours.

研究组 & 干预措施

Dexmedetomidine group

Experimental

Dexmedetomidine is infused at a rate of 0.1 ug/kg/h for a maximum of 3 days.

干预措施: Dexmedetomidine (Drug)

Placebo group

Placebo Comparator

Placebo (normal saline) is infused at a same rate as in the dexmedetomidine group for a maximum of 3 days.

干预措施: Placebo (normal saline) (Drug)

结局指标

主要结局

Incidence of delirium within the first 7 days after enrollment

时间窗: From enrollment until 7 days.

Assessment twice daily (in the morning from 0600 h to 1000 h and in the evening from 1800 h to 2000 h) with the Confusion Assessment Method for the ICU (CAM-ICU).

次要结局

  • 30-day life quality(On the 30th day after enrollment.)
  • Duration of mechanical ventilation(From enrollment until extubation or 30 days.)
  • All-cause 30-day mortality(On the 30th day after enrollment.)
  • Length of stay in the ICU(From enrollment until ICU discharge or 30 days.)
  • Length of stay in the hospital(From enrollment until hospital discharge or 30 days.)
  • Occurrence of non-delirium complications(From enrollment until 30 days.)
  • 30-day cognitive function(On the 30th day after enrollment.)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Dong-Xin Wang

Professor and Chairman, Department of Anesthesiology and Critical Care Medicine

Peking University First Hospital

研究点 (1)

Loading locations...

相似试验